Drug · CHEMBL601
AMINOLEVULINIC ACID
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. AMINOLEVULINIC ACID. Drugs and targets, record CHEMBL601. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL601
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases30
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 30Source Open Targets
See all 30 diseasesTrials71
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 12 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 51 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02144077 | Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy | Phase 3 | 281 | 2019-03-11 | aminolevulinic acid | Its name | ClinicalTrials.gov |
| NCT02137785 | Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities | Phase 3 | 269 | 2015-09-16 | aminolevulinic acid | Its name | ClinicalTrials.gov |
| NCT00706433 | Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne | Phase 2 | 266 | 2009-08-21 | aminolevulinic acid | Its name | ClinicalTrials.gov |
| NCT01475955 | Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK) | Phase 2 | 235 | 2013-12-24 | aminolevulinic acid | Its name | ClinicalTrials.gov |
| NCT03573401 | Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). | Phase 3 | 187 | 2025-04-29 | aminolevulinic acid | Its name | ClinicalTrials.gov |
| NCT00002975 | Photodynamic Therapy in Treating Patients With Skin Cancer | Phase 2 | 180 | 2013-10-10 | aminolevulinic acid | Its name | ClinicalTrials.gov |
| NCT02239679 | Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy | Phase 2 | 166 | 2017-09-21 | aminolevulinic acid | Its name | ClinicalTrials.gov |
| NCT02632110 | Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face | Phase 2 | 137 | 2017-12-13 | aminolevulinic acid | Its name | ClinicalTrials.gov |
| NCT05060237 | Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp | Phase 1 | 112 | 2024-10-17 | aminolevulinic acid | Its name | ClinicalTrials.gov |
| NCT01966120 | Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT) | Phase 3 | 87 | 2016-12-19 | aminolevulinic acid | Its name | ClinicalTrials.gov |
1 to 10 of 71
See all 71 trialsComparisons in its trials16
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| BF-200 ALA vs Methyl-aminolevulinate: deaths from any cause | 0 of 138 | 1 of 143 | 281 | NCT02144077 | Trial comparisons |
| BF-200 ALA vs Methyl-aminolevulinate: serious adverse events | 3 of 138 | 7 of 143 | 281 | NCT02144077 | Trial comparisons |
| ALA-PDT vs Vehicle: Complete Clearance Rate | 42 of 135 | 17 of 134 | 269 | NCT02137785 | Trial comparisons |
| ALA-PDT vs Vehicle: Complete Clearance Rate | 35 of 135 | 12 of 134 | 269 | NCT02137785 | Trial comparisons |
| ALA-PDT vs Vehicle: serious adverse events | 5 of 135 | 2 of 134 | 269 | NCT02137785 | Trial comparisons |
| BF-200 ALA vs Vehicle: deaths from any cause | 0 of 145 | 0 of 42 | 187 | NCT03573401 | Trial comparisons |
| BF-200 ALA vs Vehicle: serious adverse events | 3 of 145 | 2 of 42 | 187 | NCT03573401 | Trial comparisons |
| BF-200 ALA vs Placebo to BF-200 ALA: serious adverse events | 2 of 55 | 0 of 32 | 87 | NCT01966120 | Trial comparisons |
| Aminolevulinic Acid vs Vehicle: serious adverse events | 0 of 35 | 0 of 35 | 70 | NCT01458587 | Trial comparisons |
| 10-minute Incubation With Microneedle Roller & Sham vs 20-minute Incubation With Microneedle Roller & Sham: deaths from any cause | 0 of 16 | 0 of 16 | 32 | NCT02594644 | Trial comparisons |
1 to 10 of 16
See all 16 comparisons in its trialsPapers from its trials23
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL601
GET https://conductscience.org/api/drugs/v1/CHEMBL601/diseases?page=2